Improving DxMultiomics, Powered by Your Choices

We're building DxMultiomics to be The Central Nexus of Biotech Intelligence. To ensure a seamless experience and continuous improvement, we utilize website analytics. These tools help us monitor site performance, understand how users navigate the platform, and identify opportunities to make your research journey more efficient. We handle this data with the utmost respect for your privacy, and you can choose what works best for you.

Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio
_↗ ir.supernus.com
News Image

Supernus Pharmaceuticals has announced a definitive agreement to acquire Sage Therapeutics for approximately $795 million, a strategic move designed to significantly bolster Supernus's presence in the CNS market and diversify its product portfolio. This acquisition centers on ZURZUVAE (zuranolone), the groundbreaking first and only FDA-approved oral medicine for postpartum depression, which will become Supernus's fourth key growth product. The deal, expected to close in the third quarter of 2025, comprises an upfront cash payment of $8.50 per share, plus a non-tradable Contingent Value Right (CVR) worth up to an additional $3.50 per share, contingent on ZURZUVAE achieving specific net sales and commercial milestones. This transaction is anticipated to generate substantial annual cost synergies of up to $200 million and is projected to be significantly accretive to Supernus's earnings by 2026, leveraging its established commercial infrastructure to expand ZURZUVAE's reach and provide a much-needed treatment option for women with postpartum depression.



Log In
Sign Up